Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 8:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,058 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Takeda Clear all
Completed Phase 2 Interventional Results available

Teduglutide for Enterocutaneous Fistula (ECF)

NCT02889393
View directory record Official record
Conditions
Postoperative Fistula
Interventions
Teduglutide, Standard of Care
Drug · Other
Lead sponsor
Daniel Dante Yeh
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 18, 2026, 8:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Taste Assessment Study of SHP429 in Healthy Adult Subjects

NCT02125292
View directory record Official record
Conditions
Healthy
Interventions
Mesalamine
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 18, 2026, 8:06 AM EDT
Recruiting Phase 3 Interventional

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

NCT05677971
View directory record Official record
Conditions
Alpha1-Antitrypsin Deficiency
Interventions
Fazirsiran Injection, Placebo
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 18, 2026, 8:06 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00735371
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
LDX 30 mg, LDX 50 mg, LDX 70 mg, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
45
States / cities
Little Rock, Arkansas • El Centro, California • Rolling Hills Estates, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 18, 2026, 8:06 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus

NCT00225277
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone, Glimepiride
Drug
Lead sponsor
Takeda
Industry
Eligibility
35 Years to 85 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
65
States / cities
Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 18, 2026, 8:06 AM EDT
Completed Phase 2 Interventional Results available

A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)

NCT03694275
View directory record Official record
Conditions
15q Duplication Syndrome, CDKL5 Deficiency Disease
Interventions
Soticlestat
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Norcross, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 18, 2026, 8:06 AM EDT
Completed No phase listed Observational

A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Young Children With Gaucher Disease

NCT04721366
View directory record Official record
Conditions
Gaucher Disease
Interventions
Standard of Care
Other
Lead sponsor
Takeda
Industry
Eligibility
Up to 5 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 18, 2026, 8:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of TAK-881 in Healthy Adults

NCT05059977
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-881
Biological
Lead sponsor
Takeda
Industry
Eligibility
19 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Oct 18, 2026, 8:06 AM EDT
Completed Phase 3 Interventional Results available

Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.

NCT01193257
View directory record Official record
Conditions
Prostate Cancer
Interventions
Orteronel, Prednisone, Orteronel Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,099 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
37
States / cities
Anchorage, Alaska • Fort Smith, Arkansas • Fountain Valley, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 18, 2026, 8:06 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years

NCT03325881
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SHP465, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 12 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
41
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 18, 2026, 8:06 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Norovirus Bivalent-Vaccine Efficacy Study

NCT01609257
View directory record Official record
Conditions
Prevention From Norovirus Infection
Interventions
Norovirus Bivalent Vaccine, Saline Comparator
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 49 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
5
States / cities
Atlanta, Georgia • Baltimore, Maryland • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 18, 2026, 8:06 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

NCT04009109
View directory record Official record
Conditions
Myeloma, Multiple
Interventions
Lenalidomide, Ixazomib, Daratumumab Injection, Dexamethasone
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years to 75 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Bangor, Maine • Boston, Massachusetts • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 18, 2026, 8:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

NCT04381650
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
TAK-981, Pembrolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
18
States / cities
Scottsdale, Arizona • Orange, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 18, 2026, 8:06 AM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant

NCT02181413
View directory record Official record
Conditions
Multiple Myeloma, Autologous Stem Cell Transplant
Interventions
Ixazomib Citrate, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
6
States / cities
Little Rock, Arkansas • Rochester, Minnesota • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 18, 2026, 8:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Soticlestat Tablets in Healthy Adults

NCT05284760
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Soticlestat
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 18, 2026, 8:06 AM EDT
Completed Phase 3 Interventional Results available

Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.

NCT00286468
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Alogliptin and glyburide, Glyburide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
54
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 18, 2026, 8:06 AM EDT
Completed Phase 1 Interventional Results available

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

NCT01425008
View directory record Official record
Conditions
Melanoma, Metastatic Melanoma, Solid Tumor, Neoplasm
Interventions
MLN2480
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
9
States / cities
San Francisco, California • Denver, Colorado • Augusta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 18, 2026, 8:06 AM EDT
Terminated Phase 2 Interventional Results available

A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy

NCT04096560
View directory record Official record
Conditions
Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2)
Interventions
TAK-994, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
36
States / cities
Alabaster, Alabama • Phoenix, Arizona • Bellflower, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 18, 2026, 8:06 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Identification of Novel Skeletal Muscle-derived Factors That Promote Lipid Oxidation (Columbus)

NCT01911091
View directory record Official record
Conditions
Obesity, Disorder of Lipid Storage and Metabolism, Lipid Metabolism Disorders, Metabolic Disorder
Interventions
Exercise
Behavioral
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 40 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 18, 2026, 8:06 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

NCT01485796
View directory record Official record
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
Immune Globulin Infusion (Human), 10%, Recombinant human hyaluronidase
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
2 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
Irvine, California • Thornton, Colorado • North Palm Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 18, 2026, 8:06 AM EDT
Completed No phase listed Observational

Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A

NCT02610127
View directory record Official record
Conditions
Acquired Hemophilia A
Interventions
OBIZUR
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
16
States / cities
Aurora, Colorado • Gainesville, Florida • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 18, 2026, 8:06 AM EDT
Completed Phase 1 Interventional Results available

Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma

NCT00963820
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ixazomib citrate
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
6
States / cities
Scottsdale, Arizona • West Hollywood, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Oct 18, 2026, 8:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Bioavailability of Teduglutide Administered Subcutaneously by Syringe Injection Versus Pen Injector in Healthy Adult Participants

NCT04465396
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Teduglutide, Syringe Injection, Pen injector
Drug · Device
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 18, 2026, 8:06 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)

NCT00262080
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
ecallantide, Phosphate Buffer Saline (PBS),
Drug
Lead sponsor
Shire
Industry
Eligibility
10 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Wheaton, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 18, 2026, 8:06 AM EDT